ReviewTrends in cancer2018
Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside.
Review in Trends in cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 283 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
283 citing papers in PubMed, 1 synthesis or guideline pooled it, 525 citations in OpenAlex.
- Collagenase-mediated extracellular matrix targeting for enhanced drug penetration and therapeutic efficacy in nanoscale delivery systems for cancer therapy.Journal of nanobiotechnology · 2025Pooled it
- Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3.The oncologist · 2026Trial
- Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial.Signal transduction and targeted therapy · 2024Trial
- Exploiting the dynamics of hyperthermia-enhanced delivery of thermosensitive liposomal doxorubicin to solid tumors.Drug delivery · 2026Article
- Early Prediction of the Breast Cancer Response to Neoadjuvant Chemotherapy Based on Intratumoral Interstitial Fluid Pressure using 3-D Subharmonic-Aided Pressure Estimation.Ultrasound in medicine & biology · 2026Article
- Beyond the dose: a clearance-enabled in vitro platform for evaluating local therapies.Drug delivery and translational research · 2026Article
- Magnetically Guided Macrophage Immunobots Coordinate Iron-Metabolic Cascades and Immunogenic Ferroptosis for Tumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineering Nanotherapeutics Through Interfacial Mechanics: Mechanobiology and Precision Drug Delivery.Micromachines · 2026Article
- Closing the recapitulation gap in obesity-conditioned TNBC drug development.npj drug discovery · 2026Review
- Multimodal transformers predict cancer therapy response from tumor mechanics.Array (New York, N.Y.) · 2026Article
- Decoding osteosarcoma mechanobiology: PIEZO channels in tumor progression, immune remodeling, and pain.Cancer metastasis reviews · 2026Review
- Computational Pathology Reveals Extracellular-Matrix Imaging Biomarkers of Therapy Response in Preclinical Breast Cancer.Cancers · 2026Article
- Review
- Breaking barriers: nano-boosted drug delivery systems in overcoming the defenses of pancreatic cancer.Molecular cancer · 2026Review
- Fresh 3D Printing of Spanlastics Hydrogel for Drug Delivery Applications In Vitro.Pharmaceutical research · 2026Article
- Atomic force microscopy-based nanomechanical signatures as cancer biomarkers in a nutshell.FEBS letters · 2026Review
- Hydrostatic pressure reduces the mechanosensitivity of cell migration.Science advances · 2026Article
- Multifunctional nanotherapeutics for tumor microenvironment modulation in solid tumor therapy.Discover nano · 2026Review
- Renaissance of Traditional Mineral Drugs in Cancer: Advanced Delivery Strategies and Bioengineering Approaches.Pharmaceutics · 2026Review
- Article
223 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Physical forces have a crucial role in tumor progression and cancer treatment. The application of principles of engineering and physical sciences to oncology has provided powerful insights into the mechanisms by which these forces affect tumor progression and confer resistance to delivery and efficacy of molecular, nano-, cellular, and immuno-medicines. Here, we discuss the mechanics of the solid and fluid components of a tumor, with a focus on how they impede the transport of therapeutic agents and create an abnormal tumor microenvironment (TME) that fuels tumor progression and treatment resistance. We also present strategies to reengineer the TME by normalizing the tumor vasculature and the extracellular matrix (ECM) to improve cancer treatment. Finally, we summarize various mathematical models that have provided insights into the physical barriers to cancer treatment and revealed new strategies to overcome these barriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.